<DOC>
	<DOCNO>NCT03054506</DOCNO>
	<brief_summary>Constipation common gastrointestinal motility disorder often chronic , negatively affect patient ' daily life . Constipation occur bowel movement become difficult less frequent.This study do study effectiveness hydrogel capsule , CSP01 , compare active control ( carboxymethylcellulose ) placebo ( non-medicine sugar pill ) , relieve constipation among subject chronic idiopathic constipation ( CIC ) irritable bowel syndrome constipation ( IBS-C ) .</brief_summary>
	<brief_title>The Effect CSP01 Chronic Idiopathic Constipation Irritable Bowel Syndrome With Constipation</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Carboxymethylcellulose Sodium</mesh_term>
	<criteria>1 . Age 2270 year old 2 . BMI &gt; 18.5 &lt; 35 kg/m2 3 . Rome III criterion functional constipation IBSC 4 . Continued IBSC CIC throughout Runin period 5 . Compliant reporting Runin ( confirm presence constipation 7day Runin baseline period ; patient require report average &lt; 3 continuous spontaneous bowel movement [ CSBMs ] ≤6 spontaneous bowel movement [ SBMs ] per week via interactive web response system ) . 6 . Ability follow verbal write instruction 7 . Ability record daily bowel habit , include frequency , stool consistency ( BSFS ) , strain ( EoPS ) , completeness evacuation , Patient Reported Outcomes ( PROs ) ( abdominal discomfort , severity constipation , bloating , overall relief ) 8 . Informed consent form sign subject 1 . History loose stool 2 . History irritable bowel syndrome diarrhea ( IBSD ) mix irritable bowel syndrome ( IBSM ) 3 . Noncompliance report Runin 4 . Patients report laxative , enema , and/or suppository usage &gt; 2 day usage prohibit medication Runin period 5 . Patients report watery stool SBM ( Type 7 Bristol Stool Form Scale [ BSFS ] ) loose ( mushy ) stool &gt; 1 SBM ( Type 6 BSFS ) absence laxatives Runin 6 . GI motility obstruction GI tract structural abnormality 7 . Current use prescribe illicit opioids 8 . History pelvic floor dysfunction 9 . Need manual maneuver order achieve BM 10 . History GI lumen surgery time GI abdominal operation within 60 day prior entry study 11 . History highdose stimulative cathartic laxative abuse judge investigator team 12 . Neurological disorder , metabolic disorder , significant disease would impair ability participate study 13 . Cardiovascular disease , diabetes , cancer , Crohn 's disease , ulcerative colitis 14 . BMI &lt; 18.5 &gt; 35 kg/m2 15 . Pregnancy ( positive serum urine pregnancy test ( ) females childbearing potential ) lactation 16 . Absence contraception female childbearing potential 17 . History allergic reaction carboxymethylcellulose , citric acid , sodium stearyl fumarate , raw cane sugar , gelatin , titanium dioxide 18 . Administration investigational product within 1 month prior Screening Visit 19 . Exclusion colonic inertia symptom &lt; 1 BM per 2 week 20 . Subjects anticipate surgical intervention study 21 . Known history diabetes ( type 1 2 ) 22 . History eat disorder include binge eating ( except mild binge eater ) 23 . Supine SBP &gt; 160 mm Hg and/or supine DBP &gt; 95 mm Hg ( mean two consecutive reading ) 24 . Angina , coronary bypass , myocardial infarction within 6 month prior Screening Visit 25 . History swallow disorder 26 . Esophageal anatomic abnormality ( e.g. , web , diverticuli , ring ) 27 . History gastric bypass gastric surgery 28 . History small bowel resection ( except relate appendectomy ) 29 . History gastroesophageal reflux disease 30 . History gastric duodenal ulcer 31 . History gastroparesis 32 . History abdominal radiation treatment 33 . History pancreatitis 34 . History intestinal stricture ( e.g. , Crohn 's disease ) 35 . History intestinal obstruction subject high risk intestinal obstruction include suspect small bowel adhesion 36 . History malabsorption 37 . History sucrose intolerance 38 . History hepatitis B C 39 . History human immunodeficiency virus 40 . History cancer within past 5 year ( except adequatelytreated localized basal cell skin cancer situ uterine cervical cancer ) 41 . Any clinically significant disease interfere assessment Gelesis100 , accord Investigator ( e.g. , disease require corrective treatment , potentially lead study discontinuation ) 42 . HbA1c &gt; 8.5 % ( &gt; 69 mmol/mol ) 43 . Positive test drug urine 44 . Any relevant biochemical abnormality interfere assessment Gelesis100 , accord Investigator 45 . Antidiabetic medication within 1 month prior Screening Visit ( except stable dose metformin , ≤ 1500 mg/day , least 1 month subject type 2 diabetes ) 46 . Medications require mandatory administration meal lunch dinner 47 . Anticipated requirement use prohibit concomitant medication</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>